# Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/contact-activation-inhibitor-and-factor-xi-antibody-ab023-produces-safe-dose/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Christina U. Lorentz,Norah G. Verbout,Michael Wallisch,Matthew Hagen,Joseph J. Shatzel,Sven R. Olson,Cristina Puy,Monica T. Hinds,Owen J. T. McCarty,David Gailani,András Gruber,Erik I. Tucker |
| Citations | 101 |
| DOI | 10.1161/atvbaha.118.312328 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.118.312328 |
| OpenAlex ID | https://openalex.org/W2912137362 |
| PMID | 30700130 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Sven R. Olson](https://scholariq.org/researchers/sven-r-olson/)

## Paper primary topic

- [Coagulation, Bradykinin, Polyphosphates, and Angioedema](https://scholariq.org/topics/coagulation-bradykinin-polyphosphates-and-angioedema/)

## Paper topics

- [Coagulation, Bradykinin, Polyphosphates, and Angioedema](https://scholariq.org/topics/coagulation-bradykinin-polyphosphates-and-angioedema/)
- [Blood Coagulation and Thrombosis Mechanisms](https://scholariq.org/topics/blood-coagulation-and-thrombosis-mechanisms/)
- [Hemophilia Treatment and Research](https://scholariq.org/topics/hemophilia-treatment-and-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.